Tuberculosis research update

Tropical Medicine and International Health

Volumn 15, Issue 8, 2010, Pages 981-989

  Hanekom, W A ^a   Lawn, S D ^b,c   Dheda, K ^b,d   Whitelaw, A ^b,e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

diagnosis; drug resistance; HIV; tuberculosis; vaccine

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIGEN; BCG VACCINE; CORTICOSTEROID; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG; VACCINE; VPM 1002;

BIOASSAY; COHORT ANALYSIS; EPIDEMIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS; PUBLIC HEALTH; TEMPORAL ANALYSIS; TUBERCULOSIS; TWENTY FIRST CENTURY; VACCINATION;

BACTERIUM CULTURE; CLINICAL TRIAL; DISEASE ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; MICROSCOPY; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION; OUTCOME ASSESSMENT; REVIEW; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; TUBERCULOSIS IMMUNE RECONSTITUTION; URINE LEVEL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; HUMANS; TUBERCULOSIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77954747591     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2010.02568.x     Document Type: Review

References (78)

1. Abdool-Karim SS, Churchyard GJ, Karim QA Lawn SD (2009) HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet, 6736 ed, 41 43.
2. Abu-Raddad LJ, Sabatelli L, Achterberg JT et al. (2009) Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proceedings of the National Academy of Sciences of the United States of America, 106, 13980 13985.
3. Ahmed AB, Abubakar I, Delpech V et al. (2007) The growing impact of HIV infection on the epidemiology of tuberculosis in England and Wales: 1999 2003. Thorax, 62, 672 676.
4. Albalak R, O'brien RJ, Kammerer JS et al. (2007) Trends in tuberculosis/human immunodeficiency virus comorbidity, United States 1993-2004. Archives of Internal Medicine, 167, 2443 2452.
5. Anthony RM, Kolk AH, Kuijper S Klatser PR (2006) Light emitting diodes for auramine O fluorescence microscopic screening of Mycobacterium tuberculosis. The International Journal of Tuberculosis and Lung Disease, 10, 1060 1062.
6. Arias M, Mello FC, Pavon A et al. (2007) Clinical evaluation of the microscopic-observation drug-susceptibility assay for detection of tuberculosis. Clinical Infectious Diseases, 44, 674 680.
7. Barnard M, Albert H, Coetzee G, O'brien R Bosman ME (2008) Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. American Journal of Respiratory and Critical Care Medicine, 177, 787 792.
8. Bateman C (2007) XDR TB - humane confinement 'a priority'. South African Medical Journal, 97, 1026 1030.
9. Ben Amor Y, Nemser B, Singh A, Sankin A Schluger N (2008) Underreported threat of multidrug-resistant tuberculosis in Africa. Emerging Infectious Diseases, 14, 1345 1352.
10. Breen RA, Smith CJ, Cropley I, Johnson MA Lipman MC (2005) Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy? AIDS 19, 1201 1206.
11. Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P Kambugu A (2009) Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clinical Infectious Diseases, 49, 965 972.
12. Caviedes L, Lee TS, Gilman RH et al. (2000) Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. The Tuberculosis Working Group in Peru. Journal of Clinical Microbiology, 38, 1203 1208.
13. Cox H, Mcdermid C, Coetzee D et al. (2009) Prevalence of drug resistant tuberculosis and association with HIV in Khayelitsha, South Africa. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa.
14. Dao DN, Sweeney K, Hsu T et al. (2008) Mycolic acid modification by the mmaA4 gene of M. tuberculosis modulates IL-12 production. PLoS Pathogens, 4, e1000081.
15. Dheda K, Shean K Zumla A (2009) Early treatment outcomes of extensively drug-resistant tuberculosis in South Africa are poor regardless of HIV status. 18th Annual Congress of the European Respiratory Society. Vienna, Austria.
16. Diacon AH, Pym A, Grobusch M et al. (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis. New England Journal of Medicine, 360, 2397 2405.
17. Eisenhut M, Paranjothy S, Abubakar I et al. (2009) BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. Vaccine, 27, 6116 6120.
18. Fitzgerald D (2009) Early versus delayed ART: results from Haiti. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa.
19. Forbes EK, Sander C, Ronan EO et al. (2008) Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. Journal of Immunology, 181, 4955 4964.
20. Gandhi NR, Moll A, Sturm AW et al. (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet, 368, 1575 1580.
21. Girardi E, Sabin CA, D'Arminio Monforte A et al. (2005) Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clinical Infectious Diseases, 41, 1772 1782. (Pubitemid 41759864)
22. Grode L, Seiler P, Baumann S et al. (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. Journal of Clinical Investigation, 115, 2472 2479.
23. Hamasur B, Bruchfeld J, Haile M et al. (2001) Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine. Journal of Microbiol Methods, 45, 41 52.
24. Hanekom WA, Abel B Scriba TJ (2007) Immunological protection against tuberculosis. South African Medical Journal, 97, 973 977.
25. Hanscheid T (2008) The future looks bright: low-cost fluorescent microscopes for detection of Mycobacterium tuberculosis and Coccidiae. Transactions of the Royal Society of Tropical Medicine and Hygiene, 102, 520 521.
26. Hesseling AC, Rabie H, Marais BJ et al. (2006) Bacille Calmette-Guerin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clinical Infectious Diseases, 42, 548 558.
27. Hillemann D, Rüsch-Gerdes S Richter E (2009) Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. Journal of Clinical Microbiology, 47, 1767 1772.
28. Hoft DF (2008) Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet, 372, 164 175.
29. Horwitz MA, Harth G, Dillon BJ Maslesa-Galic S (2006) A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. Vaccine, 24, 1593 1600.
30. Hung NV, Sy DN, Anthony RM, Cobelens FG Van Soolingen D (2007) Fluorescence microscopy for tuberculosis diagnosis. The Lancet Infectious Diseases, 7, 238 239.
31. Kagina BM, Abel B, Bowmaker M et al. (2009) Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. Vaccine, 27, 5488 5495.
32. Katiyar SK, Bihari S, Prakash S, Mamtani M Kulkarni H (2008) A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease, 12, 139 145.
33. Kehinde AO, Obaseki FA, Ishola OC Ibrahim KD (2007) Multidrug resistance to Mycobacterium tuberculosis in a tertiary hospital. Journal of the National Medical Association, 99, 1185 1189.
34. Lange C, Pai M, Drobniewski F Migliori GB (2009) Interferon-gamma release assays for the diagnosis of active tuberculosis: sensible or silly? European Respiratory Journal, 33, 1250 1253.
35. Lawn SD, Bekker LG Wood R (2005a) How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 19, 1113 1124.
36. Lawn SD, Badri M Wood R (2005b) Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. Aids 19, 2109 2116.
37. Lawn SD, Bekker LG Miller RF (2005c) Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. The Lancet Infectious Diseases 5, 361 373.
38. Lawn SD, Myer L, Bekker LG Wood R (2006) Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 20, 1605 1612.
39. Lawn SD, Myer L, Bekker LG Wood R (2007) Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 21, 335 341.
40. Lawn SD, Wilkinson RJ, Lipman MC Wood R (2008) Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. American Journal of Respiratory and Critical Care Medicine, 177, 680 685.
41. Lawn SD, Myer L, Edwards D, Bekker LG Wood R (2009a) Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS, 23, 1717 1725.
42. Lawn SD, Kranzer KK Wood R (2009b) Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clinics in Chest Medicine, 30, 685 699.
43. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG Wood R (2009c) Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS, 23, 1875 1880.
44. Lazarus JV, Olsen M, Ditiu L Matic S (2008) Tuberculosis-HIV co-infection: policy and epidemiology in 25 countries in the WHO European region. HIV Medicine, 9, 406 414.
45. Mansoor N, Scriba TJ, De Kock M et al. (2009) HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guerin vaccine. Journal of Infectious Diseases 199, 982 990.
46. Marais BJ, Brittle W, Painczyk K et al. (2008) Use of light-emitting diode fluorescence microscopy to detect acid-fast bacilli in sputum. Clinical Infectious Diseases, 47, 203 207.
47. Martin C, Williams A, Hernandez-Pando R et al. (2006) The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine, 24, 3408 3419.
48. McShane H, Pathan AA, Sander CR et al. (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Medicine, 10, 1240 1244.
49. Meintjes G, Lawn SD, Scano F et al. (2008) Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. The Lancet Infectious Diseases, 8, 516 523.
50. Meintjes G, Rangaka MX, Maartens G et al. (2009a) Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clinical Infectious Diseases, 48, 667 676.
51. Meintjes G, Wilkinson RJ Morroni C (2009b) Randomised placebo-controlled trial of prednisone for TB IRIS. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada.
52. Meskel DW, Abate G, Lakew M, Goshu S Aseffa A (2008) Anti-tuberculosis drug resistance among retreatment patients seen at St Peter Tuberculosis Specialized Hospital. Ethiopian Medical Journal, 46, 219 225.
53. Middelkoop K, Wood R, Myer L et al. (2009) Widespread ART is associated with the decline in TB prevalence. 5th IAS conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa.
54. Mitnick C, Bayona J, Palacios E et al. (2003) Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. New England Journal of Medicine, 348, 119 128.
55. Mitnick CD, Mcgee B Peloquin CA (2009) Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opinion on Pharmacotherapy, 10, 381 401.
56. Moore D, Ekwaru P, Liechty C, Were W, Mwima G Solberg P (2006) Prevalence, incidence and outcomes of tuberculosis treatment in HIV+ individuals initiating home-based antiretroviral therapy in rural Uganda. 13th Conference on Retroviruses and Opportunistic Infections. Denver, Colorado, USA.
57. Mutetwa R, Boehme C Dimairo M (2009) Evaluation of a Commercial Urine Lipoarabinomannan ELISA kit for Diagnosis of TB in a High HIV Prevalence Setting. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada.
58. Nunn P, Zignol M, Jaramillo E, Wright A Getahun H (2007) Tb drug resistance: is it really a threat to Africa? Ethiopian Medical Journal, 45, 399 404.
59. Pfyffer GE, Welscher HM, Kissling P et al. (1997) Comparison of the Mycobacteria Growth Indicator Tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli. Journal of Clinical Microbiology, 35, 364 368.
60. Reed S Lobet Y (2005) Tuberculosis vaccine development; from mouse to man. Microbes and Infection, 7, 922 931.
61. Schaaf HS, Moll AP Dheda K (2009) Multidrug and extensively drug-resistant tuberculosis in Africa and South America: epidemiology, diagnosis and management in adults and children. Clinics in Chest Medicine, 30, 667 683.
62. Shah M, Variava E, Holmes CB et al. (2009) Diagnostic Accuracy of a Urine Lipoarabinomannan Test for Tuberculosis in Hospitalized Patients in a High HIV Prevalence Setting. Journal of Acquired Immune Deficiency Syndromes, 52, 145 151.
63. Shean KP, Willcox PA, Siwendu SN et al. (2008) Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa 1992-2002. The International Journal of Tuberculosis and Lung Disease, 12, 1182 1189.
64. Singh JA, Upshur R Padayatchi N (2007) XDR-TB in South Africa: no time for denial or complacency. PLoS Medicine, 4, e50.
65. Somoskovi A, Clobridge A, Larsen SC et al. (2006) Does the MGIT 960 system improve the turnaround times for growth detection and susceptibility testing of the Mycobacterium tuberculosis complex? Journal of Clinical Microbiology, 44, 2314 2315.
66. Soysal A, Millington KA, Bakir M et al. (2005) Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet, 366, 1443 1451.
67. Steingart KR, Henry M, Ng V et al. (2006) Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. The Lancet Infectious Diseases, 6, 570 581. (Pubitemid 44262344)
68. Tessema TA, Hamasur B, Bjun G, Svenson S Bjorvatn B (2001) Diagnostic evaluation of urinary lipoarabinomannan at an Ethiopian tuberculosis centre. Scandinavian Journal of Infectious Diseases, 33, 279 284.
69. Umubyeyi AN, Vandebriel G, Gasana M et al. (2007) Results of a national survey on drug resistance among pulmonary tuberculosis patients in Rwanda. The International Journal of Tuberculosis and Lung Disease, 11, 189 194.
70. United Nations (2008) The Millenium Development Goals Report 2008.
71. Weinrich Olsen A, Van Pinxteren LA, Meng Okkels L, Birk Rasmussen P Andersen P (2001) Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infection and Immunity, 69, 2773 2778.
72. WHO (2007) Revised BCG vaccination guidelines for infants at risk for HIV infection. Weekly Epidemiological Record, 82, 193 196.
73. WHO (2008a) Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy Statement, June 2008.
74. WHO (2008b) Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2008.
75. WHO (2009) Global tuberculosis control 2009: epidemiology, strategy, financing.
76. Williams BG Dye C (2003) Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science, 301, 1535 1537.
77. Wright A, Zignol M, Van Deun A et al. (2009) Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet, 373, 1861 1873.
78. Yew WW Leung CC (2008) Management of multidrug-resistant tuberculosis: update 2007. Respirology, 13, 21 46.